Currency In USD
| Previous Close | 1.97 |
| Open | 1.95 |
| Day High | 1.99 |
| Day Low | 1.89 |
| 52-Week High | 3.79 |
| 52-Week Low | 0.82 |
| Volume | 261,567 |
| Average Volume | 4.77M |
| Market Cap | 14.41M |
| PE | -0.61 |
| EPS | -3.15 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 1.5 |
| Change | -0.06 |
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investo
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptan
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- B